Oral Session 1-7C Multiple Myeloma: Multicenter Clinical Trials

[OS1-7C-4] Elotuzumab plus pom/dex for RRMM: F/U of efficacy/safety in a Japanese sub-analysis of ELOQUENT-3

Shigeki Ito¹, Mitsuo Hori², Naoki Takezako³, Kazutaka Sunami⁴, Junya Kuroda⁵, Mihaela Popamckiver⁶, Yingming Jou⁶, Suresh Shelat⁶, Masafumi Miyoshi⁷, Kenshi Suzuki⁸ (1.Department of Clinical Oncology, Iwate Medical University Hospital, 2.Department of Hematology, Ibaraki Prefectural Central Hospital, Kasama, Japan, 3.National Hospital Organization Disaster Medical Center, Tokyo, Japan, 4.National Hospital Organization Okayama Medical Center, Okayama, Japan, 5.Div. Hematol. Oncol., Kyoto Prefectural University of Medicine, Kyoto, Japan, 6.Bristol-Myers Squibb, Princeton, NJ, USA, 7.Bristol-Myers Squibb K.K., Tokyo, Japan, 8.Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan)